JCO Precision Oncology · Nov 9, 2026
Cancer Risks Associated With Germline BARD1 Pathogenic/Likely Pathogenic Variants: A Multicenter Study of 445 Families
By Homer JP, Demeure MJ, Yao Y et al.
Purpose: To estimate the relative and absolute risks (ARs) for ovarian, prostate, male and female breast, pancreatic, biliary tract, and colorectal cancers associated with germline BARD1 pathogenic and likely pathogenic variants (PVs/LPVs) because these risks have not previously been reported from a genotype-first perspective. Methods: We performed a secondary retrospective analysis of multicenter data comprising 445 three-generation pedigrees with confirmed BARD1 PVs/LPVs from 25 institutions nationwide. Data were aggregated at the family-relatedness level. The risks were estimated using a Bayesian survival model that incorporated information from the Surveillance, Epidemiology, and End Results (SEER) Program. Results: We confirmed the previously established increased risk for female breast cancer (relative risk [RR] = 3.53; 95% CI, 1.95 to 5.81; posterior probability [PP] = 0.0040) and found positive associations with female pancreatic cancer (RR = 3.76 [95% CI, 2.16-7.25]; PP < .0001), male pancreatic cancer (RR = 2.89 [95% CI, 1.66 to 5.61]; PP < .0001), and prostate cancer (RR = 3.02 [95% CI, 1.95 to 4.71]; PP < .0001). The predictive ARs to age 85 were 41.84% (95% CI, 23.09 to 68.91) for female breast cancer, 4.80% (95% CI, 2.76 to 9.25) for female pancreatic cancer, 3.98% (95% CI, 2.29 to 7.73) for male pancreatic cancer, and 36.11% (95% CI, 23.29 to 56.29) for prostate cancer. Risk estimates suggest an association for male breast, ovarian, and female colorectal cancers; however, the clinical significance is unclear, and these findings warrant cautious interpretation. In contrast, we found no evidence of association for biliary tract cancer or male colorectal cancer. Conclusion: These results support BARD1 's association with female breast cancer and suggest associations with pancreatic and prostate cancers. These findings have potential implications for genetic counseling and personalized risk management for male and female BARD1 PV/LPV heterozygotes.